| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | a1AGP |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组a1AGP(alpha-1-acid glycoprotein)的假设参考文献示例，内容基于典型研究方向整理而成：
---
1. **文献名称**：*High-Yield Expression of Recombinant Human Alpha-1-Acid Glycoprotein in HEK293 Cells and Its Glycosylation Profiling*
**作者**：Chen L, et al.
**摘要**：本研究利用HEK293哺乳动物表达系统成功表达了重组人a1AGP，并通过质谱分析证实其糖基化修饰与天然蛋白高度相似。实验表明，重组蛋白在体外具有与免疫细胞结合的能力，为后续功能研究奠定了基础。
2. **文献名称**：*Functional Characterization of Recombinant Alpha-1-Acid Glycoprotein in Drug Binding and Release*
**作者**：Martinez R, et al.
**摘要**：通过表面等离子体共振技术(SPR)分析了重组a1AGP与多种药物的结合特性，发现其与抗炎药物(如地塞米松)的亲和力与天然蛋白一致，提示其在药物递送系统中的潜在应用。
3. **文献名称**：*Anti-Inflammatory Effects of Recombinant a1AGP in Sepsis Models*
**作者**：Kim S, et al.
**摘要**：在小鼠脓毒症模型中，重组a1AGP显著降低了促炎细胞因子(如TNF-α和IL-6)的水平，并改善了生存率，表明其作为炎症性疾病治疗剂的潜力。
4. **文献名称**：*Optimization of Recombinant a1AGP Production in Pichia pastoris for Large-Scale Applications*
**作者**：Gomez P, et al.
**摘要**：开发了一种在毕赤酵母中高效表达重组a1AGP的工艺，通过发酵条件优化实现了克级产量，且蛋白具有与天然a1AGP相似的免疫调节活性。
---
**注**：以上文献为示例性整理，具体研究需参考真实发表的学术论文。如需实际文献，建议在PubMed或Web of Science中检索关键词“recombinant alpha-1-acid glycoprotein”或“recombinant ORM1”。
Alpha-1-acid glycoprotein (a1AGP), also known as orosomucoid, is a 41-43 kDa plasma glycoprotein belonging to the lipocalin family. It is synthesized primarily in the liver and consists of a single polypeptide chain with five N-linked glycosylation sites, contributing to ~45% of its molecular weight. As an acute-phase reactant, a1AGP levels rise significantly during inflammation, infection, or trauma, modulating immune responses and maintaining homeostasis. Its biological functions include binding and transporting hydrophobic molecules (e.g., steroids, drugs), inhibiting neutrophil chemotaxis, and regulating apoptosis.
The recombinant form of a1AGP (ra1AGP) is produced using expression systems like mammalian cells (e.g., CHO, HEK293) or yeast to mimic native glycosylation patterns critical for its activity. Unlike plasma-derived a1AGP, recombinant production ensures batch consistency, scalability, and reduced risk of pathogen contamination. Research highlights its therapeutic potential in inflammatory diseases, sepsis, and cancer, where it may attenuate excessive immune activation. Additionally, ra1AGP’s drug-binding properties are studied for pharmacokinetic modulation, as it influences the bioavailability of medications like antivirals and antidepressants.
Recent studies also explore its role in mitigating oxidative stress and neuroinflammation, suggesting applications in neurodegenerative disorders. Despite progress, challenges remain in optimizing glycosylation profiles and understanding structure-function relationships. ra1AGP continues to serve as a vital tool for elucidating pathophysiological mechanisms and developing targeted therapies.
×
